Oligomerix, Inc.

[On Demand]
Oligomerix has a clear and de-risked line-of-sight into the clinic with its lead tau inhibitor of self-association which works at the beginning of the tau cascade to prevent tau aggregation which leads to Alzheimer's and other dementia's. Transition to Ph 1 human clinical trials are expected to be initiated in late 2022.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
OLX07010 - small molecule inhibitor of tau self assocation
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Oligomerix, Inc.